cholecalciferol and calcifediol-lactone

Topics: 24,25-Dihydroxyvitamin D 3; Animals; Bone and Bones; Calcifediol; Cartilage; Chick Embryo; Cholecalciferol; Dehydrocholesterols; Dihydroxycholecalciferols; Humans; Parathyroid Hormone; Vitamin D

In the present work the effect of subcutaneous administration of 250, 500 and 750 microg (10.000, 20.000 and 30.000 IU, respectively) of vitamin D3 (calciferol) daily for eight days, on serum concentrations of vitamin D3 and 25-hydroxyvitamin D3 (25-OH-D3) and on serum and tissue concentrations of Ca, Zn, Cu and Fe in 45 white male Wistar rats, aged 12 weeks and weighing 180-200 g, have been studied. The group control was integrated by 15 healthy rats with similar characteristics (strain, gender, age and weight) that treated animals. Administration of high doses of calciferol produced a hypervitaminosis D characterized by a significant (p < 0.05) increase in serum vitamin D3 and 25-OH-D3, diverse clinical signs (such as, anorexia, marked loss of body weight, bloody diarrhea, bilateral conjunctivitis, and death), hypercalcemia, hypozincaemia, hypercupremia, hypoferraemia and an alteration in the tissue distribution of Ca, Zn, Cu and Fe as compared with untreated controls. Hypercalcemia and inflammation are prominent findings in hypervitaminosis D. Inflammation or infection induce systemic changes, collectively known as the acute phase response. Among the varied alterations that together produce this response are hypoferraemia, hypozincaemia and hypercupremia. It is likely that these responses are mediated, in part, by production and release of cytokines such as interleukin 1, interferons (IFN-alpha), interleukin 6 (11-6) and tumor necrosis factor (TNF). The development of hypoferraemia during inflammation requires hepcidin, an iron regulatory hormone, a disulfide-rich peptide, produced in the liver in response to the release of I1-6 during inflammation/infection. In conclusion, our results provide evidence that short-term administration of high doses of vitamin D determined diverse clinical signs and produced a marked increase of serum vitamin D3 and 25-OH-D3 and a marked alteration in the serum and tissue concentrations of Ca, Zn, Cu, and Fe. These changes depend on the doses given of vitamin D.

Topics: Animals; Calcifediol; Calcium; Cholecalciferol; Copper; Hypercalcemia; Injections, Subcutaneous; Iron; Kidney; Liver; Male; Rats; Rats, Wistar; Vitamins; Zinc

23,25-Dihydroxyvitamin D3 was isolated from vitamin D-toxic pig plasma by sequential chromatography through two gravity columns and three high performance liquid chromatography systems. Two of the high performance liquid chromatography systems separated the R and S diastereomers of 23,25-dihydroxyvitamin D3 and demonstrated that the metabolite has the 23S configuration. Ultraviolet absorbance and mass spectroscopy of the pure metabolite and mass spectroscopy of its trisilylated derivative confirmed the structural assignment. 23S,25-Dihydroxyvitamin D3, 23R,25-dihydroxyvitamin D3, 25S,26-dihydroxyvitamin D3, and 25R,26-dihydroxyvitamin D3 were assessed for their ability to produce 25-hydroxyvitamin D3-26,23-lactone in vitamin D2-toxic rats. On 23S,25-dihydroxyvitamin D3, of the naturally occurring compounds, was able to increase the plasma lactone concentration. This metabolite was a more efficient precursor than 25-hydroxyvitamin D3, suggesting that 23S-hydroxylation is a rate-limiting step in 25-hydroxyvitamin D3-26,23-lactone formation. 23S,25-Dihydroxyvitamin D3 was not detected in 25-hydroxyvitamin D3-dosed rats, indicating that the former is rapidly metabolized. Nephrectomized rats had a diminished but significant ability to synthesize 25-hydroxyvitamin D3-26,23-lactone from 25-hydroxyvitamin D3. Nephrectomy did not affect synthesis of 25-hydroxyvitamin D3-26,23-lactone from 23S,25-dihydroxyvitamin D3. These results demonstrate that vitamin D3 23S-hydroxylase(s) are also located extrarenally and that extrarenal tissues are quantitatively important to 25-hydroxyvitamin D3-26,23-lactone synthesis.

Topics: Animals; Calcifediol; Cholecalciferol; Chromatography, High Pressure Liquid; Dihydroxycholecalciferols; Ergocalciferols; Female; Hydroxycholecalciferols; Male; Mass Spectrometry; Nephrectomy; Rats; Rats, Inbred Strains; Swine

Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows. Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml). None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period. Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died. There was widespread metastatic calcification in the cows that died. Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.

Topics: 25-Hydroxyvitamin D 2; Animals; Calcifediol; Calcium; Cattle; Cattle Diseases; Cholecalciferol; Ergocalciferols; Female; Hydroxycholecalciferols; Hydroxyproline; Hypercalcemia; Injections, Intramuscular; Labor, Obstetric; Magnesium; Phosphorus; Pregnancy

Vitamin D supplemented rats produce a metabolite of 25-hydroxy[3 alpha-3H]vitamin D3 that is easily separated from known metabolites by using high-performance liquid chromatography. The production of this metabolite in vivo as well as 1,25-dihydroxyvitamin D3, 24(R),25-dihydroxyvitamin D3, and 25-hydroxyvitamin D3 26,23-lactone is largely if not totally eliminated by nephrectomy. Kidney homogenates from vitamin D supplemented chickens incubated with 25-hydroxyvitamin D3 produce significant quantities of the new, unknown metabolite. This metabolite was isolated in pure form from such incubation mixtures by using both straight-phase and reversed-phase high-performance liquid chromatography. This metabolite has been positively identified as 23,25-dihydroxyvitamin D3 by ultraviolet absorption spectrophotometry, mass spectrometry, and derivatization. This structure was confirmed by chemical synthesis of both C-23 stereoisomers. Although the natural product exactly comigrates with one of the synthetic isomers, the exact stereochemistry of the natural product remains unknown. It is possible that this new metabolite is an intermediate in the biosynthesis of 25-hydroxyvitamin D3 26,23-lactone.

Topics: Animals; Calcifediol; Chickens; Cholecalciferol; Chromatography, High Pressure Liquid; Dihydroxycholecalciferols; Hydroxycholecalciferols; Mass Spectrometry; Nephrectomy; Rats; Spectrophotometry, Ultraviolet; Stereoisomerism

Here we report the use of newly developed and established techniques for the determination of plasma levels of a broad spectrum of vitamin D3 metabolites, including vitamin D3 and 25OHD3-lactone, in normal humans, chronic renal failure patients, and anephric subjects. The methodology described consisted of methanol-methylene chloride extraction, Lipidex-5000 chromatography with stepwise gradient elution, normal-phase HPLC with concave gradient elution, and sensitive ligand-binding assays. The results of the study strongly suggest an extrarenal source(s) for 24,25(OH)2D3 and 25,26(OH)2D3 and indicate that both 25OHD3-lactone and 1,25(OH)2D3 may be produced solely in the kidney of the human. Significant reductions or nondetectable plasma levels of vitamin D3 in the renal disease patients may reflect abnormalities in the hepatobiliary-intestinal and/or cutaneous metabolism of vitamin D.

Topics: 24,25-Dihydroxyvitamin D 3; Calcifediol; Calcitriol; Cholecalciferol; Dihydroxycholecalciferols; Humans; Hydroxycholecalciferols; Kidney Failure, Chronic; Methods; Nephrectomy

Topics: Animals; Biotransformation; Calcifediol; Cholecalciferol; Chromatography, High Pressure Liquid; Dihydroxycholecalciferols; Ergocalciferols; Hydroxycholecalciferols; Male; Mass Spectrometry; Radioisotope Dilution Technique; Rats; Tritium

Topics: Animals; Calcifediol; Cholecalciferol; Dihydroxycholecalciferols; Hydroxycholecalciferols; Kinetics; Lactones; Male; Nephrectomy; Rats; Species Specificity; Swine

Topics: 24,25-Dihydroxyvitamin D 3; Animals; Calcifediol; Calcitriol; Cholecalciferol; Cytochrome P-450 Enzyme System; Dihydroxycholecalciferols; Humans; Hydroxycholecalciferols; Intestine, Small; Kidney; Mitochondria; Radioisotope Dilution Technique; Skin; Tritium; Vitamin D